Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-6768 in advanced solid tumors
NCT06925581Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Alpha Emitters, Beta Emitters, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-6768 in solid tumor, sponsored by Hengrui. Started Apr 2025; status: recruiting.
02
Drugs
HRS-6768
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06925581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925581.